Eagle Pharmaceuticals, Inc. (EGRX): Price and Financial Metrics


Eagle Pharmaceuticals, Inc. (EGRX): $52.29

0.57 (+1.10%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

EGRX POWR Grades


  • Value is the dimension where EGRX ranks best; there it ranks ahead of 99.24% of US stocks.
  • The strongest trend for EGRX is in Momentum, which has been heading down over the past 52 weeks.
  • EGRX ranks lowest in Momentum; there it ranks in the 4th percentile.

EGRX Stock Summary

  • For EGRX, its debt to operating expenses ratio is greater than that reported by merely 21.98% of US equities we're observing.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.38 for Eagle Pharmaceuticals Inc; that's greater than it is for merely 19.5% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Eagle Pharmaceuticals Inc is reporting a growth rate of 367.55%; that's higher than 93.48% of US stocks.
  • Stocks that are quantitatively similar to EGRX, based on their financial statements, market capitalization, and price volatility, are NTNX, PSTG, STXS, BMRA, and MOTS.
  • Visit EGRX's SEC page to see the company's official filings. To visit the company's web site, go to www.eagleus.com.

EGRX Valuation Summary

  • EGRX's EV/EBIT ratio is 21.4; this is 26.96% lower than that of the median Healthcare stock.
  • Over the past 92 months, EGRX's EV/EBIT ratio has gone up 46.7.
  • Over the past 92 months, EGRX's price/sales ratio has gone down 6.4.

Below are key valuation metrics over time for EGRX.

Stock Date P/S P/B P/E EV/EBIT
EGRX 2021-08-31 3.7 3.6 38.2 21.4
EGRX 2021-08-30 3.4 3.3 34.6 19.2
EGRX 2021-08-27 3.3 3.2 34.0 18.7
EGRX 2021-08-26 3.3 3.2 33.9 18.7
EGRX 2021-08-25 3.3 3.3 34.6 19.2
EGRX 2021-08-24 3.4 3.3 35.2 19.5

EGRX Growth Metrics

  • The 3 year revenue growth rate now stands at 263.76%.
  • Its 2 year revenue growth rate is now at -6.98%.
  • Its year over year revenue growth rate is now at -4.73%.
Over the past 49 months, EGRX's revenue has gone down $56,658,000.

The table below shows EGRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 189.217 44.458 18.307
2021-03-31 183.031 56.817 14.439
2020-12-31 187.802 49.497 11.989
2020-09-30 186.144 26.536 4.937
2020-06-30 177.363 31.523 -4.512
2020-03-31 192.127 32.963 2.469

EGRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EGRX has a Quality Grade of B, ranking ahead of 93.99% of graded US stocks.
  • EGRX's asset turnover comes in at 0.738 -- ranking 36th of 681 Pharmaceutical Products stocks.
  • ACUR, XENE, and KMPH are the stocks whose asset turnover ratios are most correlated with EGRX.

The table below shows EGRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.738 0.756 0.315
2021-03-31 0.719 0.735 0.316
2020-12-31 0.671 0.758 0.264
2020-09-30 0.664 0.761 0.184
2020-06-30 0.628 0.732 0.068
2020-03-31 0.677 0.711 0.109

EGRX Price Target

For more insight on analysts targets of EGRX, see our EGRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $48.50 Average Broker Recommendation 1.67 (Moderate Buy)

EGRX Stock Price Chart Interactive Chart >

Price chart for EGRX

EGRX Price/Volume Stats

Current price $52.29 52-week high $58.25
Prev. close $51.72 52-week low $36.48
Day low $51.59 Volume 78,600
Day high $53.20 Avg. volume 113,489
50-day MA $52.38 Dividend yield N/A
200-day MA $46.30 Market Cap 684.84M

Eagle Pharmaceuticals, Inc. (EGRX) Company Bio


Eagle Pharmaceuticals focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company was founded in 2007 and is based in Woodcliff Lake, New Jersey.


EGRX Latest News Stream


Event/Time News Detail
Loading, please wait...

EGRX Latest Social Stream


Loading social stream, please wait...

View Full EGRX Social Stream

Latest EGRX News From Around the Web

Below are the latest news stories about Eagle Pharmaceuticals Inc that investors may wish to consider to help them evaluate EGRX as an investment opportunity.

Bendamustin Market Size Report [2021-2028] | Share, Growth, Trends, Analysis, Competitive Landscape, Restrains, Forecast Research

Top Players Covered in the Bendamustin Market Research Report Teva Pharmaceutical Industries Ltd., Eisai Co., Ltd., Mundipharma International., Mylan N.V., NATCO Pharma Limited., Emcure Pharmaceuticals Ltd, Eagle Pharmaceuticals, Inc. and other key market players. Top Players Covered in the Bendamustin Market Research Report Teva Pharmaceutical Industries Ltd., Eisai Co., Ltd., Mundipharma International., Mylan N.V., NATCO Pharma Limited., Emcure Pharmaceuticals Ltd, Eagle Pharmaceuticals, Inc. and other key market players.

Intrado Digital Media | October 8, 2021

We Think Eagle Pharmaceuticals (NASDAQ:EGRX) Can Manage Its Debt With Ease

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

Yahoo | September 22, 2021

Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021

WOODCLIFF LAKE, N.J., September 07, 2021--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) ("Eagle" or the "Company") will host an investor event, led by Scott Tarriff, Chief Executive Officer, and Judi Ng-Cashin, Chief Medical Officer, and will feature other guest speakers, to discuss the CAL02 opportunity, the current treatment landscape and the unmet medical need in treating patients with severe pneumonia as follows:

Yahoo | September 7, 2021

Eagle Pharmaceuticals to Present at September Healthcare Conferences

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at two upcoming investor conferences as follows: Conference: Morgan Stanley 19th Annual Global Healthcare Conference Date: Tuesday, September 14, 2021 Time: 2:00 p.m. ET Webcast: https://morganstanley.webcasts.com/starthere.jsp?ei=1488970&tp_key=c1aabe315b Conference:

Business Wire | September 1, 2021

Company News for Sep 1, 2021

Companies in the news are: NTES, SONN, EGRX, ZEV

Yahoo | September 1, 2021

Read More 'EGRX' Stories Here

EGRX Price Returns

1-mo -3.22%
3-mo 9.30%
6-mo 27.60%
1-year 11.68%
3-year -5.44%
5-year -19.47%
YTD 12.28%
2020 -22.49%
2019 49.12%
2018 -24.58%
2017 -32.67%
2016 -10.52%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8693 seconds.